Literature DB >> 23148286

Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202.

Heather J Ribaudo1, Eric S Daar, Camlin Tierney, Gene D Morse, Katie Mollan, Paul E Sax, Margaret A Fischl, Ann C Collier, David W Haas.   

Abstract

The UGT1A1*28 variant has been associated with hyperbilirubinemia and atazanavir discontinuation. Protocol A5202 randomly assigned human immunodeficiency virus type 1 (HIV-1)-infected patients to receive atazanavir/ritonavir (atazanavir/r) or efavirenz, with tenofovir/emtricitabine or abacavir/lamivudine. A total of 646 atazanavir/r recipients were evaluable for UGT1A1. Homozygosity for *28/*28 was present in 8% of whites, 24% of blacks, and 18% of Hispanics and was associated with increased bilirubin concentrations. There was an association between *28/*28 and increased atazanavir/r discontinuation among Hispanic participants (P = .005) but not among white or black participants (P = .79 and P = .46, respectively). The positive predictive value of 28*/28* for atazanavir/r discontinuation among Hispanic participants was only 32% (95% confidence interval, 16%-52%).

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23148286      PMCID： PMC3537445          DOI： 10.1093/infdis/jis690

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  14 in total

1.  Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir/ritonavir through 96 weeks in the CASTLE study.

Authors:  Cheryl McDonald; Jonathan Uy; Wenhua Hu; Victoria Wirtz; Salome Juethner; David Butcher; Donnie McGrath; Awny Farajallah; Graeme Moyle
Journal:  AIDS Patient Care STDS       Date:  2012-03-09       Impact factor: 5.078

2.  In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation.

Authors:  Donglu Zhang; Theodore J Chando; Donald W Everett; Christopher J Patten; Shangara S Dehal; W Griffith Humphreys
Journal:  Drug Metab Dispos       Date:  2005-08-23       Impact factor: 3.922

3.  Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia.

Authors:  Margalida Rotger; Patrick Taffe; Gabriela Bleiber; Huldrych F Gunthard; Hansjakob Furrer; Pietro Vernazza; Henning Drechsler; Enos Bernasconi; Martin Rickenbach; Amalio Telenti
Journal:  J Infect Dis       Date:  2005-09-09       Impact factor: 5.226

4.  Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.

Authors:  Paul E Sax; Camlin Tierney; Ann C Collier; Eric S Daar; Katie Mollan; Chakra Budhathoki; Catherine Godfrey; Nasreen C Jahed; Laurie Myers; David Katzenstein; Awny Farajallah; James F Rooney; Belinda Ha; William C Woodward; Judith Feinberg; Karen Tashima; Robert L Murphy; Margaret A Fischl
Journal:  J Infect Dis       Date:  2011-10-15       Impact factor: 5.226

5.  Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study.

Authors:  Rebekah L Puls; Preeyaporn Srasuebkul; Kathy Petoumenos; Christoph Boesecke; Chris Duncombe; Waldo H Belloso; Jean-Michel Molina; Lin Li; Anchalee Avihingsanon; Brian Gazzard; David A Cooper; Sean Emery
Journal:  Clin Infect Dis       Date:  2010-10-01       Impact factor: 9.079

6.  Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.

Authors:  Eric S Daar; Camlin Tierney; Margaret A Fischl; Paul E Sax; Katie Mollan; Chakra Budhathoki; Catherine Godfrey; Nasreen C Jahed; Laurie Myers; David Katzenstein; Awny Farajallah; James F Rooney; Keith A Pappa; William C Woodward; Kristine Patterson; Hector Bolivar; Constance A Benson; Ann C Collier
Journal:  Ann Intern Med       Date:  2011-02-14       Impact factor: 25.391

7.  Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.

Authors:  Paul E Sax; Camlin Tierney; Ann C Collier; Margaret A Fischl; Katie Mollan; Lynne Peeples; Catherine Godfrey; Nasreen C Jahed; Laurie Myers; David Katzenstein; Awny Farajallah; James F Rooney; Belinda Ha; William C Woodward; Susan L Koletar; Victoria A Johnson; P Jan Geiseler; Eric S Daar
Journal:  N Engl J Med       Date:  2009-12-01       Impact factor: 91.245

8.  Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice.

Authors:  R M M Cleijsen; M E van de Ende; F P Kroon; F Verduyn Lunel; P P Koopmans; L Gras; F de Wolf; D M Burger
Journal:  J Antimicrob Chemother       Date:  2007-08-17       Impact factor: 5.790

9.  Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the Italian atazanavir expanded access program and MASTER Cohorts.

Authors:  C Torti; G Lapadula; A Antinori; T Quirino; R Maserati; F Castelnuovo; F Maggiolo; A De Luca; G Paraninfo; F Antonucci; G Migliorino; A Lazzarin; G Di Perri; G Rizzardini; R Esposito; G Carosi
Journal:  Infection       Date:  2009-05-26       Impact factor: 3.553

10.  Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.

Authors:  Jean-Michel Molina; Jaime Andrade-Villanueva; Juan Echevarria; Ploenchan Chetchotisakd; Jorge Corral; Neal David; Graeme Moyle; Marco Mancini; Lisa Percival; Rong Yang; Alexandra Thiry; Donnie McGrath
Journal:  Lancet       Date:  2008-08-23       Impact factor: 79.321
View more
  16 in total

Review 1.  Pharmacogenomics of antimicrobial agents.

Authors:  Ar Kar Aung; David W Haas; Todd Hulgan; Elizabeth J Phillips
Journal:  Pharmacogenomics       Date:  2014       Impact factor: 2.533

Review 2.  Perspectives on pharmacogenomics of antiretroviral medications and HIV-associated comorbidities.

Authors:  David W Haas; Philip E Tarr
Journal:  Curr Opin HIV AIDS       Date:  2015-03       Impact factor: 4.283

3.  PharmGKB summary: atazanavir pathway, pharmacokinetics/pharmacodynamics.

Authors:  Maria Alvarellos; Chantal Guillemette; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2018-05       Impact factor: 2.089

Review 4.  Germline genetic variants with implications for disease risk and therapeutic outcomes.

Authors:  Amy L Pasternak; Kristen M Ward; Jasmine A Luzum; Vicki L Ellingrod; Daniel L Hertz
Journal:  Physiol Genomics       Date:  2017-09-08       Impact factor: 3.107

5.  Atazanavir and other determinants of hyperbilirubinemia in a cohort of 1150 HIV-positive patients: results from 9 years of follow-up.

Authors:  Claudie Laprise; Jean-Guy Baril; Serge Dufresne; Helen Trottier
Journal:  AIDS Patient Care STDS       Date:  2013-07       Impact factor: 5.078

6.  Genetic variation in the UGT1A locus is associated with simvastatin efficacy in a clinical practice setting.

Authors:  Otito F Iwuchukwu; QiPing Feng; Wei-Qi Wei; Lan Jiang; Min Jiang; Hua Xu; Joshua C Denny; Russell A Wilke; Ronald M Krauss; Dan M Roden; C Michael Stein
Journal:  Pharmacogenomics       Date:  2014-11       Impact factor: 2.533

7.  Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202.

Authors:  Daniel H Johnson; Charles Venuto; Marylyn D Ritchie; Gene D Morse; Eric S Daar; Paul J McLaren; David W Haas
Journal:  Pharmacogenet Genomics       Date:  2014-04       Impact factor: 2.089

Review 8.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing.

Authors:  R S Gammal; M H Court; C E Haidar; O F Iwuchukwu; A H Gaur; M Alvarellos; C Guillemette; J L Lennox; M Whirl-Carrillo; S S Brummel; M J Ratain; T E Klein; B R Schackman; K E Caudle; D W Haas
Journal:  Clin Pharmacol Ther       Date:  2015-11-09       Impact factor: 6.875

Review 9.  Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy.

Authors:  Andrew Owen; Steve Rannard
Journal:  Adv Drug Deliv Rev       Date:  2016-02-23       Impact factor: 15.470

10.  Screening for UGT1A1 Genotype in Study A5257 Would Have Markedly Reduced Premature Discontinuation of Atazanavir for Hyperbilirubinemia.

Authors:  Saran Vardhanabhuti; Heather J Ribaudo; Raphael J Landovitz; Ighovwerha Ofotokun; Jeffrey L Lennox; Judith S Currier; Lana M Olson; David W Haas
Journal:  Open Forum Infect Dis       Date:  2015-07-01       Impact factor: 3.835
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.